Arkolith/Insider Trading/ELVN/Form 4

Heyman Richard A.

DirectorEnliven Therapeutics, Inc. (ELVN) · full profile →Form 4 · filed Jan 12, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$348K
Net Open-Market Flow
-$348K
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 9, 2026Sell(S)4K$25.00$107K25K
Jan 8, 2026Sell(S)8K$25.04$201K29K
Jan 8, 2026Sell(S)2K$25.00$41K26K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001584759-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML